Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor

Published By Datamonitor

Generics giant Teva [TEVA] has agreed to acquire Italian generics company Dorom from Pfizer for $80 million, becoming the largest generics company in Italy. Over the longer term, continued geographical expansion will counteract Teva's recent share price drop and reduce the company's dependence on key branded products like Copaxone.

Published By Datamonitor

Targacept's investigational neuronal nicotinic receptor agonist has failed to meet its primary endpoint in a Phase II trial in adults with attention deficit hyperactivity disorder. Datamonitor expects that future development focus for TC-5619 will shift towards schizophrenia, in view of Phase II data demonstrating efficacy in the treatment of cognitive dysfunction associated with the condition.

Published By Datamonitor

Worth $8 billion in 2006, the HIV market is expected undergo significant changes as it expands to an estimated $11.5 billion in 2016. Patent expiries on key drugs and product launches in new and existing classes are set to reshape the HIV treatment paradigm. One player set to lose out as its ageing HIV portfolio loses its patent protection is the current market leader, GlaxoSmithKline.